Navigation Links
Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
Date:10/24/2013

Geneva, Switzerland (PRWEB) October 24, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.

Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bioeurope/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at http://www.prweb.com/releases/selexis_bio_europe/protiens_antibodies/prweb11264432.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Targeted therapeutics for colon cancer to be presented at AACR meeting
9. NYU Langone experts present research, clinical advances at neurosurgeons meeting
10. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Gevir, a ... deer antler velvet, announced its products are coming soon to Amazon.com, the world’s largest ... Shelley Thomson as a means to develop an effective natural treatment for Shelley’s Multiple ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing a ... have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be ... are free from the shame, stigma, and harmful labeling believed to prevent ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... N.J. (PRWEB) , ... February 22, 2017 , ... ... a one-size-fits-all approach, leads to fewer trips the emergency room, fewer hospital admissions, ... The American Journal of Managed Care® (AJMC®) finds. The study can be found ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, ... or not filling a prescription because they could not afford to pay for ... medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... -- a condition where an organ of the ... weak abdominal wall. Hernia is classified into five ... hernia, umbilical hernia, and other (hiatal hernia and ... performed using a mesh, made-up of biological or ... the available options, open tension-free repair procedures and ...
(Date:2/22/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), today announced ... ended December 31, 2016. ... This news release should be read ... discussion and analysis for the years ended December 31, 2016 ... available at www.sedar.com and on the Company,s website ...
(Date:2/22/2017)... Feb. 22, 2017 astic drugs develop from ... antineoplastic drug aiming at functions at multiple links. Research ... a new stage. Download the full report: ... nearly four million cases of new tumors in ... population, environmental pollution caused by industrialization and lifestyles changed ...
Breaking Medicine Technology: